GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Also Read: GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations The vaccine is currently approved for active immunization to prevent RSV-LRTD in ...

During the same period, the company received roughly $6.9 billion of net cash proceeds from the sale of its shares of Haleon, a consumer health joint venture with GSK. In Pfizer's Q3 earnings call ...